Radnet Stock Fair Value – RADNET Reports Q2 FY2023 Earnings on August 9th

August 24, 2023

🌥️Earnings Overview

RADNET ($NASDAQ:RDNT) announced their financial reports for the second quarter of FY2023, ending June 30 2023, on August 9 2023. Total revenue reached USD 403.7 million, a 13.9% rise from the same quarter in the previous year. Net income was also up 5.9%, with a total of USD 8.4 million.

Market Price

On Wednesday, August 9th, RADNET reported their Q2 FY2023 earnings. At market open, the stock opened at $31.9 and ended the day at $31.5, a drop of 0.7% from the previous day’s closing price of $31.7. As a result, the company saw a decrease in its overall value and a red mark on its balance sheet. Analysts remain cautious in their outlook of the Q2 earnings report, with some expressing concerns about RADNET’s ability to keep up with the competition.

Despite the drop in stock price, the company was able to report increased revenue and improved margins for their Q2 performance. Going forward, RADNET plans to focus on further developing their technology and expanding their customer base to ensure long-term stability. Investors will be closely watching RADNET’s upcoming quarter and hope that the company can start to turn things around and deliver more positive results. Live Quote…

About the Company

  • RADNET_Reports_Q2_FY2023_Earnings_on_August_9th”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Radnet. RADNET_Reports_Q2_FY2023_Earnings_on_August_9th”>More…

    Total Revenues Net Income Net Margin
    1.53k -12.9 -1.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Radnet. RADNET_Reports_Q2_FY2023_Earnings_on_August_9th”>More…

    Operations Investing Financing
    181.36 -256.87 334.57
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Radnet. RADNET_Reports_Q2_FY2023_Earnings_on_August_9th”>More…

    Total Assets Total Liabilities Book Value Per Share
    2.71k 1.94k 8.85
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Radnet are shown below. RADNET_Reports_Q2_FY2023_Earnings_on_August_9th”>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    12.8% 22.2% 5.0%
    FCF Margin ROE ROA
    -5.9% 10.4% 1.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Radnet Stock Fair Value

    GoodWhale recently conducted an analysis of RADNET‘s financials, and based on our proprietary Valuation Line, we concluded that RADNET’s fair value share is around $22.5. However, its current stock price traded at $31.5, which is overvalued by 40.1%. Our analysis indicated that the stock is currently overpriced and investors should be cautious when investing in RADNET. We recommend that investors should do further research and also consider the current market trends before making any decision. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company offers a full range of imaging services, including MRI, PET/CT, CT, X-ray, ultrasound, mammography, and nuclear medicine. RadNet has a network of over 250 outpatient imaging centers in 25 states. The company’s competitors include Lantheus Holdings Inc, Todos Medical Ltd, and Medical Imaging Corp. RadNet’s competitive advantage lies in its comprehensive range of services, nationwide footprint, and strong relationships with referring physicians.

    – Lantheus Holdings Inc ($NASDAQ:LNTH)

    Lantheus Holdings Inc is a holding company that focuses on the development and commercialization of diagnostic and therapeutic imaging agents and products that help healthcare providers improve patient care. It operates through two segments: Diagnostics and Therapeutics. The Diagnostics segment provides products and services for the diagnosis of certain diseases and conditions. The Therapeutics segment provides products and services for the treatment of certain diseases and conditions.

    – Todos Medical Ltd ($OTCPK:TOMDF)

    Todos Medical Ltd is a biotechnology company that focuses on the development and commercialization of blood tests for the early detection of cancer and other diseases. The company’s market cap is 19.09M as of 2022 and has a Return on Equity of 43.06%. The company’s products are designed to provide accurate and sensitive results that can be used to guide treatment decisions.

    – Medical Imaging Corp ($OTCPK:MEDD)

    Medical Imaging Corporation is a leading provider of medical imaging solutions. The company offers a full range of medical imaging products and services, including X-ray, MRI, and CT scanners. Medical Imaging Corporation is dedicated to providing the highest quality medical imaging products and services to its customers. The company’s products are used by hospitals, clinics, and physicians around the world.


    RADNET reported strong second quarter earnings for FY2023, with total revenue increasing 13.9% year over year to USD 403.7 million and net income increasing 5.9% to USD 8.4 million. Analysts have cited the company’s strong performance in its core business areas as a key driver in these results, which is a positive sign for potential investors. Additionally, RADNET’s financials continue to improve quarter over quarter, demonstrating the company’s commitment to long-term success. With solid fundamentals and a favorable outlook, RADNET is an attractive option for investors seeking returns from a stable and growing company.

    Recent Posts

    Leave a Comment